Can Axicabtagene Ciloleucel treat liver cancer?

Axicabtagene Ciloleucel is a CAR-T cell therapy commonly used to treat certain types of hematological cancers, especially relapsed or refractory large B cell lymphoma. However, it is not suitable for treating liver cancer.

Liver cancer, also known as hepatocellular carcinoma (Hepatocellular Carcinoma, HCC), is a malignant tumor that originates in liver tissue. Unlike hematological cancers, liver cancer is a solid tumor that usually grows inside the liver rather than in the blood and bone marrow.

The mechanism of CAR-Tcell therapy involves modifying a patient's T cells so that they can more effectively recognize and attack blood cancer cells, but this approach is not suitable for treating solid tumors such as liver cancer. Treatment for liver cancer typically includes surgical resection, liver transplantation, radiation therapy, chemotherapy, targeted therapy, and other treatments designed to remove or reduce the size of the tumor, control its growth, and improve patient survival.

CAR-Tcell therapy shows potential as an innovative cancer treatment in certain types of blood cancers, but it requires specific receptor antigens to recognize and attack, which are typically expressed on blood cancer cells. Therefore, for solid tumors, such as liver cancer, CAR-T cell therapy is not the first choice treatment method.

If a patient is diagnosed with liver cancer, medical professionals will develop a treatment plan that is best suited to their specific situation in order to maximize the chance of treatment success. Treatment plans usually take into account the tumor's size, location, stage, and the patient's overall health. Patients should work closely with their doctor to follow a treatment plan and have regular check-ups to ensure optimal results.